Home    Back

Pirfenidone 267 mg [esbriet]    (DrugBank: Pirfenidone)

1 disease
IDDisease name (Link within this page)Number of trials
228Bronchiolitis obliterans1

228. Bronchiolitis obliterans    [ 92 clinical trials,   125 drugs,   (DrugBank: 34 drugs),   33 drug target genes,   152 drug target pathways]
Searched query = "Bronchiolitis obliterans", "Obliterating bronchiolitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 92 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03315741
(ClinicalTrials.gov)		March 1, 20185/10/2017The Safety and Tolerability of Pirfenidone for BOS After HCTThe Safety and Tolerability of Pirfenidone for Bronchiolitis Obliterans Syndrome After Hematopoietic Cell TransplantationBronchiolitis Obliterans;Graft Vs Host DiseaseDrug: Pirfenidone 267 MG [Esbriet]Stanford UniversityGenentech, Inc.Recruiting18 YearsN/AAll30Phase 1United States